Class summary at a glance.

Every drug in the Interleukin-36 Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $12.1Mcombined across class
Total Rx claims: 490140 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Spesolimab-Sbzo

Brand: SPEVIGO · 490 Part D claims (CY24) · 140 beneficiaries · First FDA approval: 2022-09-01

Brand-only (no generics) 56 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $12.1M

Class share

100%

of class CY24 spend

View profile →

Spesolimab

Brand: SPEVIGO · — Part D claims (CY24) · First FDA approval: 2026-03-09

Brand-only (no generics)